anokion
Anokion is harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance.
anokion has raised €73M across 2 funding rounds from 1 investor, most recently a round in Oct 2022. Based in Ecublens, Switzerland; founded 2010; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€73M
€72,528,960
Funding rounds
2
Investors
1
distinct backers
Active since
2019-10
latest 2022-10
Funding by year
EUR raised per yearanokion — funding by year — interactive chart.
Data table
| anokion — funding by year | |
|---|---|
| 2019 | €37M |
| 2022 | €36M |
Signals
High confidenceRaise-next likelihood6
base rate 30% for Other
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Exit likelihood8
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▼ Old (16y) — past typical exit age
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-10-19 | Other | €36M | Pfizer Breakthrough Growth Initiative | View deal → |
| 2019-10-01 | Series B | €37M | — | View deal → |
Investors
1Related news
- Anokion Raises $35M in Equity Funding from Pfizerfinsmes.com · 2022-10
- unquote.com
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData